Dr Audrey-Flore Ngomsik

The 2026 Nobel Prize in Chemistry went to Henri Kagan and Kenso Soai. They showed how a chemical reaction that starts almost fifty-fifty ends with one mirror image only. I explain their work in plain words, with spearmint, a drawer of gloves and the thalidomide scandal. Then I apply the same test to corporate sustainability across People, Planet and Profit, from a herbicide that cut its dose by up to 40% to CSRD reports that count tonnes and euros but say little about how they are arranged.

The 2026 Nobel Prize in Medicine went to Karl Deisseroth, Peter Hegemann and Georg Nagel for optogenetics, a light switch that turns chosen brain cells on and off. I explain the science in plain words, with a green alga that swims toward light and a blind patient who regained partial sight. Then I hold it next to corporate sustainability. Most CSR reports measure activity the way neuroscience did before 2005. They record correlations and never test causes, across People, Planet and Profit.

Pink October has pushed breast cancer screening since 1985, yet new cases still rise in half the countries studied by IARC in 2025. This ESG Audit runs the pink ribbon through E, S and G: the endocrine disruptors missing from prevention advice, safety limits built around the male body, and the board accountability gap before the EU CLP deadline of 1 November 2026. It ends with the business model that makes a company pay for what goes into its product.